Welcome to MetabolixCare
Targeted Metabolic Support for Cancer Patients
MetabolixCare – Powering Your Body’s Defense Against Metabolic disorder: A Science-Backed Approach to Cellular Healing regulating the underlying Metabolic Dysfunction.
Restore your metabolism. Strengthen your body’s defenses.
CASE STUDY
K. H. (Female, 7)
- Initially presented with – Headaches once per week
- 3 months later: HEADACHES DAILY, TREATED WITH IBUPROFEN PROGRESSED TO DIZZINESS AND IMBALANCE;
- CT SCAN: OBSTRUCTIVE LARGE HIGH RISK MEDULLOBLASTOMA, obstructing 4th Ventricle OBSTRUCTIVE HYDROCEPHALUS with Metastasis in suprasellar region;
- One month later: ADMITTED TO INTENSIVE CARE– OPERATION TO RESECT TUMOUR
- POSTOPERATIVE: Paralysis of Right arm, Bulbar and Cerebellar symptoms Diplopia Strabismus
- FOLLOWED BY CHEMOTHERAPY – Cyclophosphamide and Radiotherapy
- At this point – Commenced Mitochondrial Support Therapy
- Continued Radiotherapy for 3 months
- 7 months later – Follow-up – SLIGHT DIPLOPIA, SLIGHT RIGHT ARM WEAKNESS
- 11 months after start of Mitochondrial support – NO NEUROLOGICAL SIGNS MRI and CT SCAN – NORMAL BACK AT SCHOOL
CASE STUDY
K. H. (Female, 7)
- Initially presented with – Headaches once per week
- 3 months later: HEADACHES DAILY, TREATED WITH IBUPROFEN PROGRESSED TO DIZZINESS AND IMBALANCE;
- CT SCAN: OBSTRUCTIVE LARGE HIGH RISK MEDULLOBLASTOMA, obstructing 4th Ventricle OBSTRUCTIVE HYDROCEPHALUS with Metastasis in suprasellar region;
- One month later: ADMITTED TO INTENSIVE CARE– OPERATION TO RESECT TUMOUR
- POSTOPERATIVE: Paralysis of Right arm, Bulbar and Cerebellar symptoms Diplopia Strabismus
- FOLLOWED BY CHEMOTHERAPY – Cyclophosphamide and Radiotherapy
- At this point – Commenced Mitochondrial Support Therapy
- Continued Radiotherapy for 3 months
- 7 months later – Follow-up – SLIGHT DIPLOPIA, SLIGHT RIGHT ARM WEAKNESS
- 11 months after start of Mitochondrial support – NO NEUROLOGICAL SIGNS MRI and CT SCAN – NORMAL BACK AT SCHOOL
How MetabolixCare Supports Your Cancer Journey
MetabolixCare supports individuals on their cancer journey by restoring metabolic and cellular function,
reducing inflammation and toxins, easing chemotherapy side effects, and promoting long-term recovery. Through targeted mitochondrial/metabolic support and personalized care, the program enhances energy, recovery, and overall wellness.
01
Metabolic & Cellular Repair Support
Cancer and its treatments disrupt cellular energy production and repair mechanisms. Our program provides essential nutrients to optimize mitochondrial function, and to help correct disturbed metabolic function, maintain energy levels and support cellular recovery.
02
Anti-Inflammatory & Detoxification Support
Chronic inflammation and toxin buildup are common challenges during treatment. Our protocol helps modulate inflammatory pathways and supports the body’s natural detox systems.
03
Reduction of side effects during Chemotherapy
Mitochondrial support has been observed consistently to reduce side effects from concurrent chemotherapy and radiotherapy .
04
Long-Term Recovery & Wellness
Beyond active treatment, we focus on restoring metabolic balance, reducing recurrence risks, and promoting sustained vitality through personalized, science-backed care.
What Are You Waiting For...
Ask a Question or book a Consultation
If you are interested in learning more about our targeted Metabolic Support Plan fill in the contact form or send your inquiry via email.
Reclaim Health at the Cellular Level
A Breakthrough Protocol for Metabolic Recovery
At MetabolixCare, we focus on addressing the foundational drivers of the complex metabolic dysfunction common to cancer patients. Our approach is built on the understanding that dysfunctional cell activity as seen in cancer stems from underlying cellular and mitochondrial dysfunction — issues that are often overlooked in conventional medicine.
This program is designed to support individuals by targeting the underlying metabolic dysfunction often present at the cellular level – specifically within the mitochondria. Drawing on over 60 years of combined clinical experience, the outlined protocol offers a comprehensive outpatient strategy to help improve health outcomes through mitochondrial repair and metabolic restoration.
Individualized Health Assessment
Every individual has a unique medical history, genetic background, and current condition. A consultation ensures the protocol is tailored to your specific needs and avoids interactions with existing treatments or medications.
Nutrient-Based Supplementation
Carefully formulated nutrient combinations support mitochondrial health during the cancer journey. These are based on years of clinical research and precision dosing to maximize efficacy.
Innovative Support & Therapies
The protocol incorporates selected off-label medications and cutting-edge supplements shown to significantly support metabolic function in individuals affected by cancer.
Why Mitochondrial Medicine?
The core elements of this support protocol are specifically designed to target the metabolic dysfunctions typical for cancer and are believed to underlie the supportive benefits observed in clinical use – particularly the mitigation of side effects from treatment.
01
Nutrient Support
Nutrients help regulate the immune system, enhancing the body’s ability to detect and respond to abnormal cells. For cancer patients, this means better immune surveillance and potentially reduced risk of infections during treatment.
02
Mitochondrial Support Nutraceuticals
Healthy mitochondria are essential for proper metabolic function. These supplements support normal cell function, whilst creating a functional pressure on cells that do not have normal metabolism.
03
Multifaceted Metabolic Agents
Cancers rely on dysfunctional metabolism for survival. These agents help normalize disrupted metabolic pathways, limiting the nutrients cancer cells rely on while supporting healthy tissue cell function.
The Program in Detail
The MetabolixCare Program offers a proactive, personalized approach to managing and optimizing health. It offers a personalized, integrative approach to support cancer patients, focusing on metabolic health to help enhance patient outcomes.
01
Medical Consultation
Speak with a doctor from the comfort of your home, saving time and reducing stress.
02
Personalized Support Plan
Targeted interventions based on your unique profile often lead to better outcomes, and a greater chance of longer-term well-being.
03
Ongoing Support
Dealing with health challenges can be overwhelming. Our trusted support system offers reassurance, reduces anxiety, and reminds patients they’re not alone in their journey.
Appointment
Want to book a free Consultation or have a Question?
text………………….
Have a Look at Our
Case Studies
Discover remarkable turnarounds in Cases of Complex Metabolic Disease.
01.
J. S. (Male, Age 68)
The patient was admitted to intensive care with life-threatening conditions including severe heart failure, cardiogenic shock, multi-organ failure, and recurrent atrial fibrillation. During hospitalization, he was also diagnosed with advanced rectal adenocarcinoma and multiple metastases, making chemotherapy unviable. He began Mitochondrial Support Therapy and within eight months, his heart function significantly improved, metabolic disease markers returned to normal levels, and scans showed no evidence of remaining metabolic disease.
The patient showed remarkable recovery in both cardiac function and metabolic disease related markers following mitochondrial support therapy, despite initially being ineligible for conventional treatments.
02.
M. R. (Male 69)
The patient was diagnosed with multiple chronic diseases. He also had co-existing coronary heart disease, reduced heart function (ejection fraction 45%), mitral valve regurgitation, and high blood pressure. He started the standard treatment plan including hospitalization. However, due to severe side effects, he was unable to continue and therefore signed up for the Mitochondrial Support Therapy.
One year later, the results were extraordinary.
The patient’s heart function improved to an ejection fraction of 55% and during follow-up scans no visible signs of metabolic disease were found.
03.
K. H. (Female, Age 7)
The patient initially presented with weekly headaches that rapidly progressed to daily episodes, dizziness, and loss of balance. Imaging revealed a serious brain-related metabolic disease. Following emergency surgery, the patient experienced significant neurological complications, including right arm paralysis, visual disturbances, and coordination issues. She was then enrolled in Mitochondrial Support Therapy to help her body recover and manage cellular stress.
Within seven months, her neurological symptoms significantly improved. By month eleven, she showed no remaining neurological signs, and scans were clear. She successfully returned to school and resumed a normal life – demonstrating how metabolic support can aid recovery, even in high-risk, complex conditions.
04.
A. L. (Male, Age 58)
The patient was diagnosed with a widespread metabolic disease affecting multiple organs, including the lungs, liver, adrenal glands, and mediastinum. Alongside this, he suffered from coronary heart disease, mitral valve regurgitation, and hypertension, with a weakened heart function (ejection fraction at 45%). Initial standard treatment involved partial surgical removal. A few months later, he began Mitochondrial Support Therapy.
Just one year later, his progress was outstanding:
Heart function improved to an ejection fraction of 55%
Follow-up scans showed no evidence of metabolic disease in the abdomen or thorax
Have a Look at Our
Case Studies
Discover remarkable turnarounds in Cases of Complex Metabolic Disease.
01.
J. S. (Male, Age 68)
- 3 month hospital admission to intensive Care with: Heart Failure – Ejection Fraction -20% Cardiogenic shock Previous Heart Attack
- Developed multi-organ failure (kidneys and liver)
- Cardiac treatment – Initiated.
- INCIDENTAL DISCOVERY OF ADENOCARCINOMA OF THE RECTUM associated with MULTIPLE OMENTAL METASTASES
- TUMOUR MARKERS – CEA – 470, CA199 – 166
- OPERATION PERFORMED TO REMOVE RECTALTUMOUR
- SEDATED AND VENTILATED IN INTENSIVE CARE. CHEMOTHERAPY NOT INDICATED DUE TO MULTIPLE DIAGNOSES
- Discharged from hospital 3 months later on cardiac medicines.
- Heart Ejection Fraction: -30% to 35% (New York Heart Association (NYHA) – 3 classification)
- Persisting Omental Metastases from Rectal Adenocarcinoma
- Commenced Mitochondrial Support Therapy
- 8 months after: Hospital review – EJECTION FRACTION improved to 50% TUMOUR MARKERS – CEA – 1.7 (NORMAL), CA199 – 6.2 (NORMAL)
- CT BODY SCAN – NO EVIDENCE OF METASTASES SEEN
02.
M. R. (Male 69)
- Hospitalised – c/o WEIGHT LOSS, DIFFICULTY BREATHING
- DIAGNOSED – PRIMARY SMALL CELL LUNG CARCINOMA – WITH PLEURAL INVASION
- TREATED – Laser and Electro-cautery to part of tumour to open airways to affected lobe – PARTIAL RESECTION ONLY
- METASTASES TO MEDIASTINUM AND PLEURA, PALLIATIVE TREATMENT ONLY RECOMMENDED
- CT SCAN – Confirmed large mass RIGHT lobe of Lung with metastases to Mediastinum and Pleura – growth into RIGHT ATRIUM and into WALL OF OESOPHAGUS also noted
- CHEMOTHERAPY – Gemcitabine and Carboplatin – completed 4 months after hospitalisation
- One month after hospitalization – Commenced Mitochondrial Support Therapy
- 3 months after start of protocol – PET- CT – Showed still viable tumour activity in lung and pleura
- 3 months later, now on Mitochondrial therapy alone– CT SCAN – NO EVIDENCE OF TUMOUR SEEN
- 2 months after this – MRI – NO EVIDENCE OF TUMOUR SEEN
03.
K. H. (Female, Age 7)
- Presented with – Headaches once per week
- 3 months later – HEADACHES DAILY, TREATED WITH IBUPROFEN PROGRESSED TO DIZZINESS AND IMBALANCE
- CT SCAN – OBSTRUCTIVE LARGE HIGH RISK MEDULLOBLASTOMA, obstructing 4th Ventricle OBSTRUCTIVE HYDROCEPHALUS with Metastasis in suprasellar region
- One month later – ADMITTED TO INTENSIVE CARE– OPERATION TO RESECT TUMOUR
- POST OPERATIVE – Paralysis of Right arm, Bulbar and Cerebellar symptoms Diplopia Strabismus
- FOLLOWED BY CHEMOTHERAPY – Cyclophosphamide and Radiotherapy
- At this point – Commenced Mitochondrial Support Therapy
- Continued Radiotherapy for 3 months
- 7 months later – Follow-up: SLIGHT DIPLOPIA, SLIGHT RIGHT ARM WEAKNESS
- 11 months after start of Mitochondrial support: NO NEUROLOGICAL SIGNS
- MRI and CT SCAN – NORMAL BACK AT SCHOOL
04.
A. L. (Male, Age 58)
- Diagnosed with generalised Necrotic Tumour of the Lungs and metastases to Liver, Adrenal, Mediastinum
- PET SCAN – Generalised tumour of the lungs, extra-renal metastasis and mediastinal metastasis
- ULTRASOUND – 34mm SUPRARENAL MASS
- 35mm LYMPH NODE – OMENTUM
- LIVER METASTASIS – size not noted
- TREATMENT – PARTIAL RESECTION OF LUNG TUMOUR, to relieve blockage of right bronchus – not possible to remove all tumour
- CHEMOTHERAPY – Docetaxel and Carboplatin – 15 cycles planned – could only tolerate 4 cycles due to nausea and vomiting
- Commenced Mitochondrial Support Therapy February
- CT-PET SCAN – NO EVIDENCE OF TUMOUR SEEN IN ABDOMEN OR THORAX – NO INFILTRATION SEEN
What Are You Waiting For...
Ask a Question or book a Consultation
If you are interested in learning more about our targeted Metabolic Support Plan fill in the contact form or send your inquiry via email.
Opening Hours
Mon-Fri:
9 am- 5 pm
Contact
info@metabolixcare.com
coordination@metabolixcare.com
+34 644 04 36 98
What Are You Waiting For...
Ask a Question or book a Consultation
If you are interested in learning more about our targeted Metabolic Support Plan fill in the contact form or send your inquiry via email.
Opening Hours
Mon-Fri:
9 am- 5 pm
info@metabolixcare.com
coordination@metabolixcare.com
Phone
+34 644 04 36 98
